Displaying 1 - 1 of 1
| Active Ingredient | RITUXIMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia. |
| Caution | All patients should be screened for hepatitis B virus infection before starting rituximab; it should not be used in patients with active infection. Cytokine release syndrome (fever, chills, a More ... |
| Dose Range | 50 mg/hour, increased in increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour, if well tolerated. Subsequent doses may be begun at a rate of 100 mg/hour, increased in increments of 100 mg/hour every 30 minutes to a maximum of 400 mg/hou |
| Drug Interactions | |
| Pregnancy | Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletio More ... |
| Breast Feeding | Avoid breast-feeding during and for 12 months after treatment. |